GlobeNewswire: Novoheart Holdings Inc. Contains the last 10 of 64 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:40:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/18/2129058/0/en/Novoheart-Holdings-Inc-has-Closed-its-Going-Private-Transaction.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. has Closed its Going-Private Transaction2020-11-18T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan and Victor Chang, each a director of the Company, of all the issued and outstanding common shares of Novoheart (“Novoheart Shares”) other than those Novoheart Shares already owned by the Purchaser, by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”), has been completed.]]>https://www.globenewswire.com/news-release/2020/11/16/2127706/0/en/Novoheart-Holdings-Inc-Receives-Final-Order-Approving-Going-Private-Transaction.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Receives Final Order Approving Going-Private Transaction2020-11-16T19:53:30Z<![CDATA[VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan and Victor Chang, each a director of the Company, of all the issued and outstanding common shares of Novoheart (“Novoheart Shares”), other than those Novoheart Shares currently owned by certain shareholders who have entered into rollover, voting and support agreements with the Purchaser (the “Rollover Shareholders”), by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”), has received approval from the Supreme Court of British Columbia, in its final order dated November 13, 2020.]]>https://www.globenewswire.com/news-release/2020/11/11/2124384/0/en/Novoheart-Holdings-Inc-Receives-Securityholder-Approval-of-Going-Private-Transaction.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Receives Securityholder Approval of Going-Private Transaction2020-11-11T01:31:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan and Victor Chang, each a director of the Company, of all the issued and outstanding common shares of Novoheart (“Novoheart Shares”) other than those Novoheart Shares currently owned by certain shareholders who have entered into rollover, voting and support agreements with the Purchaser (the “Rollover Shareholders”), by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”), has been approved by the holders of Novoheart Shares and options (collectively, the “Securityholders”). At the special meeting of Securityholders held on November 10, 2020 (the “Meeting”), a special resolution approving the Arrangement was approved by 99.99% of the votes cast at the Meeting or by proxy by holders of Novoheart Shares, by 99.94% of the votes cast at the Meeting or by proxy by holders of Novoheart Shares, excluding the votes cast in respect of Novoheart Shares held by interested parties required to be excluded pursuant to applicable securities law, and by 99.99% of the votes cast by Securityholders.]]>https://www.globenewswire.com/news-release/2020/09/16/2094250/0/en/Novoheart-Holdings-Inc-Enters-into-Definitive-Agreements-for-Going-Private-Transaction.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Enters into Definitive Agreements for Going-Private Transaction2020-09-16T06:00:00Z<![CDATA[VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) announces that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with Novomed Limited (the “Purchaser”), a company controlled by Prof. Ronald Li, CEO and a director of the Company, pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of Novoheart (“Novoheart Shares”), other than those Novoheart Shares currently owned by certain shareholders who have entered into rollover, voting and support agreements (the “Rollover Agreements”) with the Purchaser (the “Rollover Shareholders”), for cash consideration of C$0.53 per Novoheart Share (the “Transaction”) by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”). The cash consideration price represents a 47.2% premium to the closing price of the Novoheart Shares on the TSX Venture Exchange (“TSXV”) on September 15, 2020.]]>https://www.globenewswire.com/news-release/2020/08/31/2085958/0/en/Novoheart-Holdings-Inc-Reports-Second-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Reports Second Quarter 2020 Financial Results2020-08-31T10:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).]]>https://www.globenewswire.com/news-release/2020/05/19/2035472/0/en/Novoheart-Holdings-Inc-Reports-First-Quarter-2020-Financial-Results-and-Announces-AGM-Results.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results and Announces AGM Results2020-05-19T10:00:00Z<![CDATA[VANCOUVER, British Columbia, May 19, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).]]>https://www.globenewswire.com/news-release/2020/03/11/1999101/0/en/Novoheart-Holdings-Inc-Reports-Second-Quarter-and-Fiscal-2019-Financial-Results.html?f=22&fvtc=4&fvtv=42208Novoheart Holdings Inc. Reports Second Quarter and Fiscal 2019 Financial Results2020-03-11T22:00:00Z<![CDATA[VANCOUVER, British Columbia, March 11, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).]]>https://www.globenewswire.com/news-release/2020/02/20/1987964/0/en/Novoheart-Named-2020-Venture-50-Company-Ranked-Among-Year-s-Top-Performing-Stocks-in-Life-Sciences.html?f=22&fvtc=4&fvtv=42208Novoheart Named 2020 Venture 50 Company, Ranked Among Year’s Top Performing Stocks in Life Sciences2020-02-20T14:30:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has been named a 2020 Venture 50 Company, ranked among the TSX Venture Exchange’s top 50 best performing companies.]]>https://www.globenewswire.com/news-release/2020/01/21/1972717/0/en/Novoheart-Contracts-with-Global-Pharma-to-Develop-Novel-Microplate-for-High-Throughput-Drug-Screening-Using-Engineered-Human-Heart-Tissue-Strips.html?f=22&fvtc=4&fvtv=42208Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips2020-01-21T08:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables will see Novoheart further expand its current testing capabilities of the MyHeart™ Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS). Termed the hvCTS-96, the disposable microplate is a custom-designed plate with 96 "wells" used to simultaneously cultivate 96 individual miniature hvCTS, and will be compatible with robotic plate handling systems for automated high-throughput screening.]]>https://www.globenewswire.com/news-release/2020/01/07/1966965/0/en/Continued-Success-of-Novoheart-to-Receive-R-D-Grants-Innovation-Technology-Fund-for-Developing-Smart-Cardiac-Screening-Technologies.html?f=22&fvtc=4&fvtv=42208Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies2020-01-07T08:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that its wholly owned subsidiary Novoheart Limited has been awarded a further grant from the Innovation and Technology Commission (ITC) of Hong Kong SAR Government. Combined with a cash rebate scheme and funding for hiring R&D talent, the Company is expected to receive a total of over HK$10 million ($1.67 million CAD) in grant awards from the ITC over the next 2 years. This is the third major R&D matching grant that the ITC has awarded Novoheart in recognition of the company’s pioneering work involving its award-winning MyHeart™ Platform of bioengineered human heart tissues, making the total awarded grant to over $22 million HKD ($3.7 million CAD).]]>